Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study
在进行中的第二期临床研究的HCV感染患者的前导队列中,8周的治疗表现出了97%的SVR12率。
EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance
EASL展示了高抗病毒效力,短时间治疗,低药物相互作用风险和高抗性阻碍潜力的最佳潜力。
BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced new data from the lead-in cohort (n=60) of the Company's ongoing Phase 2 combination study of bemnifosbuvir, an oral nucleotide NS5B polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, for the treatment of hepatitis C virus (HCV). With an 8-week treatment duration, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), which is the primary efficacy endpoint of the study.
2024年6月5日,波士顿(GLOBE NEWSWIRE) - Atea Pharmaceuticals,Inc.(纳斯达克:AVIR)(“Atea”)是一家处于临床阶段的生物制药公司,致力于发现和开发口服抗病毒治疗剂治疗严重病毒性疾病,今天宣布新的数据来自公司正在进行的研究的前导队列(n = 60),该研究是bemnifosbuvir和ruzasvir的组合研究,经口服核苷酸NS5B聚合酶抑制剂和口服NS5A抑制剂用于治疗丙型肝炎病毒(HCV)。根据8周的治疗经历,非肝硬化患者的第二期数据显示,12周后治疗(SVR12)的持久病毒学反应率达到97%,这是该研究的主要疗效终点。
The Company will also present preclinical data further demonstrating a high barrier to resistance and pharmacokinetics for bemnifosbuvir and a low risk of drug-drug interactions for ruzasvir. These data are being presented at the European Association for the Study of the Liver (EASL) Congress taking place June 5-8, 2024, in Milan, Italy.
该公司还将展示预临床数据,进一步证明bemnifosbuvir具有高抗性阻碍和药代动力学,而ruzasvir的药物-药物相互作用风险低。这些数据将于2024年6月5日至8日在意大利米兰举行的欧洲肝病研究协会(EASL)大会上展示。
"Today, new challenges are hindering progress towards our goal of HCV elimination in the U.S. and globally. Patient demographics have changed, and the pace of new HCV infections is quickly outpacing the rate of those being treated. It is apparent that further innovations are required to address the needs of today's HCV-infected patients," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "The data being presented at EASL demonstrate a potential best-in-class profile that combines the most compelling attributes of current HCV drug treatments through the innovative combination of bemnifosbuvir and ruzasvir. We look forward to reporting the full results from our ongoing Phase 2 study during the second half of this year."
“今天,新的挑战正在阻碍在美国和全球实现HCV消除的进展。患者人口统计数据已经改变,新发HCV感染病例的速度正在迅速超过正在接受治疗的病例的速度。显然,需要进一步创新来满足今天HCV感染患者的需求,”Atea Pharmaceuticals的首席执行官兼创始人Jean-Pierre Sommadossi博士说道。“在EASL展示的数据展示出了一种潜在的最佳组合,将当前HCV药物治疗的最具吸引力的特点集于一体,通过bemnifosbuvir和ruzasvir的创新组合。我们期待在今年下半年报告正在进行的第二阶段研究的完整结果。”
Results from the lead-in cohort of the Phase 2 study also showed a 100% SVR12 rate in participants infected with genotype 3 (n=13), a historically difficult-to-treat genotype of HCV. The combination regimen was well tolerated, with no drug-related severe adverse events (SAEs) or treatment discontinuations. Based on these positive data from the lead-in cohort, the Phase 2 study continues, with the aim of enrolling up to an additional 220 subjects, including those with compensated cirrhosis.
第二期研究的前导队列结果还显示,基因型3感染者(n = 13)的SVR12率达到100%,这是历史上难以治疗的HCV基因型。该组合方案耐受性良好,没有药物相关的严重不良事件(SAE)或治疗中止。基于前导队列的这些积极数据,第二期研究正在继续进行,旨在招募最多220名受试者,包括那些有代偿性肝硬化的人。
"Today, many of my HCV patients present with other conditions requiring multiple concurrent therapies and complicated lives," said Eric Lawitz, MD, The Texas Liver Institute, Clinical Professor of Medicine, University of Texas Health San Antonio. "I am excited about the initial bemnifosbuvir and ruzasvir combination data. The combination of a short 8-week treatment duration, a low risk of drug-drug interactions, and robust antiviral efficacy across all genotypes makes this an attractive regimen."
“今天,我的HCV患者中有很多人因患其他病症而需要接受多种同时治疗和复杂的生活方式,”德州肝脏研究所的Eric Lawitz医学博士,德克萨斯大学健康圣安东尼奥分校医学临床教授说。我对bemnifosbuvir和ruzasvir组合的初始数据感到兴奋。将短短的8周疗程,低药物相互作用的风险和所有基因型的强有力的抗病毒效力结合起来,使该疗法更具吸引力。”
More than 2 million people in the U.S. are living with chronic HCV, and approximately 100,000 new chronic cases are diagnosed each year. HCV diagnoses continually outpace annual treatment rates, as less than a third of those diagnosed with HCV receive timely treatment.
美国有超过200万人患有慢性HCV,每年诊断大约10万例新的慢性病例。HCV的诊断不断超过年度治疗率,因为仅有不到三分之一被HCV诊断的人接受及时治疗。
Data Presented at EASL Include:
EASL演示数据:
Poster Title: Lead-in Cohort Results From a Phase 2 Study of a Novel 8-Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection (THU-382)
Conclusion: Data from the lead-in cohort of 60 patients in the Phase 2 clinical trial of bemnifosbuvir and ruzasvir in HCV-infected subjects showed a high SVR12 rate of 97% in the lead-in cohort with a short 8-week duration of treatment. The primary endpoints of the study are safety and SVR12. Viral kinetics were similar in genotype 1 and genotype 3 infected subjects, including a 100% SVR12 rate in historically difficult-to-treat genotype 3 infected subjects. The combination was generally safe and well tolerated. There were no drug-related serious adverse events or treatment discontinuations, and adverse events were mostly mild.
海报标题:慢性丙型肝炎病毒感染患者新型8周组合方案Bemnifosbuvir和Ruzasvir的第二期研究的前导队列结果(THU-382)
结论:在HCV感染的受试者中,bemnifosbuvir和ruzasvir的临床试验的第二期研究中,前导队列中的60名患者的数据显示,8周的疗程具有高达97%的高SVR12率。研究的主要终点是安全性和SVR12。各基因型感染者的病毒动力学类似,包括在历史上难以治疗的基因型3感染者中实现的100%的SVR12率。这种组合通常是安全和耐受的。没有药物相关的严重不良事件或治疗中止,不良反应大多是轻微的。
Poster Title: Bemnifosbuvir is a Potent HCV NS5B Inhibitor with a Favorable Antiviral Profile and High Resistance Barrier (SAT-402)
Conclusion: Viral resistance is an important consideration for direct-acting antiviral (DAA) use as it may impact the efficacy of treatments for HCV infection. Results demonstrated that bemnifosbuvir is at least ten-fold more potent than sofosbuvir, a medication to treat HCV infections, across all genotypes tested and is not resistant to resistance-associated substitutions (RASs) that have been found to alter the activity of sofosbuvir. While the C223H mutation was found to be the primary bemnifosbuvir RAS in genotype 1b, multiple additional substitutions at other NS5B regions were required to confer meaningful resistance, suggesting that bemnifosbuvir provides a high barrier to resistance. Based upon the data demonstrated to date, it is expected that the bemnifosbuvir and ruzasvir combination should have a more compelling antiviral profile against major HCV NS5A RAVs than the current standard of care.
海报标题:Bemnifosbuvir是一种具有良好抗病毒特性和高抗性阻碍的HCV NS5B抑制剂(SAT-402)
结论:病毒抗性是直接作用抗病毒(DAA)使用的重要考虑因素,因为它可能影响HCV感染的治疗效果。结果表明,与用于治疗HCV感染的药物sofosbuvir相比,bemnifosbuvir在所有测试的基因型中至少比sofosbuvir强10倍,并且对已发现会改变sofosbuvir活性的耐药菌株(RAS)没有抗性。尽管发现C223H突变是基因型1b的主要bemnifosbuvir RAS,但在其他NS5B区域需要多个附加替换才能产生有意义的抗性,这表明bemnifosbuvir提供了很高的抗性阻碍潜力。根据迄今展示的数据,预期bemnifosbuvir和ruzasvir组合应比当前的标准疗法具有更有力的抗HCV NS5A RAVs的抗病毒特性。
Poster Title: Absorption, Distribution, Metabolism, and Excretion of [14C]-Bemnifosbuvir in Rats (SAT-411)
Conclusion: This preclinical study in rats was conducted to better understand the tissue distribution, metabolites, and excretion routes following bemnifosbuvir treatment. Following a single oral dose in rats, bemnifosbuvir has favorable overall absorption, distribution, metabolism, and excretion (ADME) properties, including good bioavailability (>60%) and wide distribution to tissues with low penetration into the brain. Bemnifosbuvir was highly and rapidly metabolized to the metabolite AT-273, consistent with the proposed metabolic and activation pathway.
海报标题:大鼠中[14C] - Bemnifosbuvir的吸收,分布,代谢和排出(SAT-411)
结论:在大鼠中进行的这项临床前研究旨在更好地了解经bemnifosbuvir治疗后的组织分布,代谢物和排出途径。在大鼠中单次口服后,bemnifosbuvir具有有利的全局吸收,分布,代谢和排出(ADME)特性,包括良好的生物利用度(> 60%)和广泛的低脑组织分布。Bemnifosbuvir在短时间内高度迅速被代谢为类似于其代谢物AT-273,与拟定的代谢和活化途径一致。
Poster Title: Low Risk of Drug-Drug Interactions for Ruzasvir Based Upon In Vitro Metabolism and Transporter Interaction Studies (SAT-412)
Conclusion: Many patients infected with HCV are also taking multiple co-medications, which may impact treatment decisions. This preclinical study aimed to further understand the risk of drug-drug interactions (DDIs) for ruzasvir by analyzing its metabolism in human liver microsomes and cells. Based on these in vitro data and static DDI risk assessment models, ruzasvir has a low potential to be a perpetrator of DDIs via inhibition or induction of CYP450. Similarly, it has a low potential to inhibit OATP1B1 and OATP1B3 transporters. The relevance of bile salt export pump (BSEP) inhibition to DDIs is limited.
海报标题:根据体外代谢和转运蛋白相互作用研究,Ruzasvir对药物-药物相互作用风险的低风险(SAT-412)体外评估Sulopenem对结论:许多HCV感染的患者还服用多种伴随治疗,可能影响治疗决策。这项临床前研究旨在进一步了解ruzasvir通过分析其在人类肝微粒体和细胞中的代谢率的药物-药物相互作用(DDI)的风险。根据这些数据和静态DDI风险评估模型,通过CYP450的抑制或诱导,ruzasvir有很低的作为施害者DDI的潜力。同样,它有很低的抑制OATP1B1和OATP1B3转运蛋白的潜力。BSEP的抑制对DDIs的相关性有限。
结论:许多HCV患者正在服用多种共同药物,这可能会影响治疗决策。这项临床前研究旨在通过分析人类肝脏微粒体和细胞中的代谢作用,进一步了解鲁扎斯韦的药物-药物相互作用(DDI)风险。基于这些数据和静态DDI风险评估模型,鲁扎斯韦具有对CYP450的抑制或诱导导致DDI的低潜力。同样,它对OATP1B1和OATP1B3转运蛋白的抑制潜力也很低。关于胆盐泵(BSEP)的抑制与DDI的相关性受到限制。在体外根据这些数据和静态DDI风险评估模型,鲁扎斯韦通过抑制或诱导CYP450具有DDI作用的潜力很低。同样,它对OATP1B1和OATP1B3转运蛋白的抑制潜力也很低。胆盐泵(BSEP)的抑制与DDI相关性有限。
About Hepatitis C Virus
关于丙型肝炎病毒
Hepatitis C virus (HCV) is a blood-borne, positive-sense, single-stranded (ss)RNA virus that primarily infects liver cells. HCV is a leading cause of chronic liver disease and liver transplants, spreading via blood transfusion, hemodialysis, and needle sticks. An estimated 50 million people globally live with chronic HCV infection, with approximately 1 million new infections and 242,000 deaths occurring each year. Most HCV-related deaths are due to liver scarring (cirrhosis) and liver cancer (hepatocellular carcinoma). Injection drug use accounts for around 30% of new HCV cases globally and approximately 60% in the U.S. Annually, HCV diagnoses in the U.S. outpace treatment rates, as less than a third of those diagnosed with HCV receive timely treatment.
丙型肝炎病毒(HCV)是一种通过血液传播的阳性单链RNA病毒,主要感染肝细胞。HCV是慢性肝病和肝移植的主要原因,通过输血、透析和针刺传播。全球约有5000万人患有慢性HCV感染,每年约有100万新感染和24.2万人死亡。大多数HCV相关死亡是由肝硬化和肝癌造成的。注射毒品在全球新HCV病例中占约30%,在美国约占60%。在美国,HCV的诊断数量超过治疗率,因为仅有不到三分之一的HCV患者能及时接受治疗。
About Bemnifosbuvir and Ruzasvir for Hepatitis C Virus (HCV)
关于伯曼肤巴和鲁扎维ρ治疗丙型肝炎病毒(HCV)
Bemnifosbuvir is an oral, purine nucleotide prodrug designed to inhibit viral replication by impairing viral RNA polymerase, a key component in the replication machinery of enveloped positive single-stranded RNA viruses, such as human coronaviruses and HCV. Atea is developing bemnifosbuvir in combination with ruzasvir, an oral NS5A inhibitor for the treatment of HCV. As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV. The combination of bemnifosbuvir and ruzasvir has exhibited synergistic in vitro activity against HCV with no pharmacokinetic (PK) drug-drug interactions in healthy volunteers.
伯曼肤巴是一种口服嘌呤核苷酸类藥物,通过损害病毒RNA聚合酶,这是隔膜型正单链RNA病毒如人类冠状病毒和HCV复制机器中的关键组成部分,以抑制病毒复制。 Atea正在研究伯曼肤巴与鲁扎维ρ,一种口服NS5A抑制剂结合起来治疗HCV。 作为单一药物,伯曼肤巴和鲁扎维ρ都表现出强有力的泛基因型抗病毒活性针对HCV。 伯曼肤巴和鲁扎维ρ的联合使用表现出对HCV的协同作用,并且在健康志愿者中没有药物动力学(PK)药物相互作用。在体外這种HCV的区间透析应进行抗病毒治疗,建议在透析前进行治疗以防止感染。 研究表明,伯曼肤巴和鲁扎维ρ合用,可以对抗HCV的活性,且与健康志愿者中没有PK药物相互作用。
In vitro studies have shown bemnifosbuvir to be approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV GT 1–5. In vitro studies have also demonstrated that bemnifosbuvir remained fully active against SOF resistance-associated strains (S282T), with up to 58-fold more potency than SOF. The PK profile of bemnifosbuvir supports once-daily dosing for the treatment of HCV. Across both HCV and COVID-19 programs, bemnifosbuvir has been administered to over 2,100 subjects and has been well-tolerated at doses up to 550 mg for durations up 12 weeks in healthy subjects and patients.
体外小鼠数据表明,用UNO局部治疗固体肿瘤癌症模型可以刺激抗肿瘤免疫反应。Beyond Cancer, Ltd. 相信UNO具有防止复发或转移性疾病的潜力,仅需单次5分钟的治疗,并具有有限的毒性或非靶向效果。研究表明,伯曼肤巴对HCV的实验室株和临床分离物(HCV GT 1-5)的活性约为索磷布韦(SOF)的10倍。体外小鼠数据表明,用UNO局部治疗固体肿瘤癌症模型可以刺激抗肿瘤免疫反应。Beyond Cancer, Ltd. 相信UNO具有防止复发或转移性疾病的潜力,仅需单次5分钟的治疗,并具有有限的毒性或非靶向效果。研究还表明,伯曼肤巴对SOF抵抗相关株(S282T)保持完全活性,比SOF具有最高高达58倍的药效。伯曼肤巴的PK药代动力学特性支持一日一次口服,用于HCV治疗。 伯曼肤巴已在HCV和COVID-19项目中向超过2100名受试者给予剂量最高可达550 mg的长达12周的治疗,患者很好地耐受了伯曼肤巴。
Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 1,200 HCV-infected patients at daily doses of up to 180 mg for 12 weeks and has demonstrated a favorable safety profile. Ruzasvir's PK profile supports once-daily dosing.
鲁扎维ρ在大规模的临床前(pico摩尔级)和临床研究中显示出高度强大的泛基因型抗病毒活性。 鲁扎维ρ已经以每天180毫克的剂量给超过1,200名HCV感染患者治疗了12周,显示出良好的安全性。
About the Phase 2 Study
关于第2期研究
Atea is currently conducting a global Phase 2 clinical trial in treatment-naïve, chronic HCV-infected patients either without cirrhosis or with compensated cirrhosis. This study is designed to evaluate the safety and efficacy of eight weeks of treatment with the combination consisting of once-daily bemnifosbuvir 550 mg and ruzasvir 180 mg. Up to approximately 280 treatment-naïve patients across all HCV genotypes, including the lead-in cohort of 60 patients without cirrhosis, are expected to be enrolled in this Phase 2 clinical trial.
Atea目前正在针对处于无肝硬化或有代偿性肝硬化状态的未接受治疗的慢性HCV感染患者进行全球第2期临床试验。该研究旨在评估每日一次伯曼肤巴550 mg和鲁扎维ρ180 mg的联合治疗8周的安全性和疗效。 预计将在该第2期临床试验中招募近280名处于各种HCV基因型状态下的未接受治疗的患者,包括60例无肝硬化的患者。
The primary endpoints of the study are safety and sustained virologic response (SVR) at 12 weeks post-treatment (SVR12). Other virologic endpoints include virologic failure, SVR at 24 weeks post-treatment (SVR24) and resistance. Topline results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
该研究的主要终点是安全性和12周治疗后持续病毒学反应(SVR)(SVR12)。其他病毒学终点包括病毒学失败、24周治疗后的持续病毒学反应(SVR24)和抗药性。 预计将在2024年下半年公布第2期研究中招募的所有患者的结果。
About Atea Pharmaceuticals
关于Atea制药公司
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV). For more information, please visit .
Atea是一家临床阶段的生物制药公司,专注于发现,开发和商业化口服抗病毒治疗药物,以满足患有严重病毒感染的患者的未满足的医疗需求。 Atea基于公司对抗病毒药物开发,核苷(酸)化学,生物学,生物化学和病毒学的深刻理解,构建了专有的核苷(酸)脂肪酸类藥物平台,以开发治疗单链核糖核酸,或ssRNA病毒的新产品候选药物,这是严重病毒性疾病流行的原因。Atea计划通过使用可与其核苷(酸)类藥物平台组合使用的其他类别的抗病毒药物来增加其抗病毒产品候选药物的管线。目前,Atea专注于开发口服抗病毒治疗严重急性呼吸综合症冠状病毒2(SARS-CoV-2)和丙型肝炎病毒(HCV)的药物。欲了解更多信息,请访问 。
Forward-Looking Statements
前瞻性声明
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company's plans relating to the date and time of the presentations at the conference, the time of anticipated release of additional clinical data and the potential of bemnifosbuvir in combination with ruzasvir to treat HCV. When used herein, words including "expects," "may," "will," "anticipates," "plans," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption "Risk Factors" in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC's website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
本新闻稿包括《1995年私人证券诉讼改革法案》(PSLRA)范围内的“前瞻性声明”。本新闻稿中的前瞻性声明包括但不限于公司有关会议演示日期和时间、预计发布的额外临床数据时间以及伯曼肤巴与鲁扎维ρ治疗HCV的潜力的计划。在本文中使用“期望”、“可能”、“将”、“预计”、“计划”和类似表达意愿的话语旨在识别前瞻性声明。此外,任何涉及对未来事件或情况的期望、信仰、计划、投射、目标、表现或其他表征,包括任何基础假设的任何陈述或信息,均属于前瞻性声明。所有前瞻性声明均基于公司当前的预期和各种假设。公司认为存在合理的依据支持其预期和信仰,但它们本质上是不确定的。公司可能无法实现其预期,而其信仰可能证明不正确。根据各种重要因素,实际结果可能会与在本新闻稿中作出的前瞻性声明所具体描述或暗示的结果有所不同,包括但不限于公司提交给SEC的报告中每个重要因素的信息,包括10-K年度报告、10-Q季度报告、8-K年度报告和其他备案文件,可在SEC的网站上www.sec.gov为之提供参考。这些和其他重要因素可能会导致实际结果与在本新闻稿中提出的前瞻性声明所表示的有所不同。这种前瞻性声明仅代表管理层在本新闻稿发布之日的估计值。尽管公司可能会在将来某个时候选择更新此类前瞻性声明,但在法律要求之外,它不承担更新的义务,即使随后的事件导致我们的看法发生变化。这些前瞻性声明不应视为代表公司在本新闻稿之后任何日期的观点。
Contacts
联系方式
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Jonae Barnes
投资者关系和企业传播高级副总裁
617-818-2985
Barnes.jonae@ateapharma.com
Will O'Connor
Precision AQ
212-362-1200
will.oconnor@precisionaq.com
Will O'Connor
Josh.Rappaport@precisionaq.com
212-362-1200
will.oconnor@precisionaq.com